Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.04
AMS's Cash to Debt is ranked lower than
84% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. AMS: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
AMS' s 10-Year Cash to Debt Range
Min: 0  Med: 0.27 Max: 1.04
Current: 0.04
0
1.04
Equity to Asset 0.37
AMS's Equity to Asset is ranked lower than
60% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. AMS: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
AMS' s 10-Year Equity to Asset Range
Min: -0.34  Med: 0.32 Max: 0.43
Current: 0.37
-0.34
0.43
F-Score: 5
Z-Score: 0.69
M-Score: -3.45
WACC vs ROIC
8.79%
0.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.29
AMS's Operating margin (%) is ranked lower than
67% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 7.05 vs. AMS: 3.29 )
Ranked among companies with meaningful Operating margin (%) only.
AMS' s 10-Year Operating margin (%) Range
Min: -20.53  Med: 11.60 Max: 45.83
Current: 3.29
-20.53
45.83
Net-margin (%) -4.71
AMS's Net-margin (%) is ranked lower than
77% of the 214 Companies
in the Global Medical Care industry.

( Industry Median: 3.29 vs. AMS: -4.71 )
Ranked among companies with meaningful Net-margin (%) only.
AMS' s 10-Year Net-margin (%) Range
Min: -6.18  Med: 6.16 Max: 57.1
Current: -4.71
-6.18
57.1
ROE (%) -3.50
AMS's ROE (%) is ranked lower than
77% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 8.45 vs. AMS: -3.50 )
Ranked among companies with meaningful ROE (%) only.
AMS' s 10-Year ROE (%) Range
Min: -4.64  Med: 7.78 Max: 1872.38
Current: -3.5
-4.64
1872.38
ROA (%) -1.12
AMS's ROA (%) is ranked lower than
74% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 3.44 vs. AMS: -1.12 )
Ranked among companies with meaningful ROA (%) only.
AMS' s 10-Year ROA (%) Range
Min: -1.37  Med: 2.53 Max: 70.39
Current: -1.12
-1.37
70.39
ROC (Joel Greenblatt) (%) 3.14
AMS's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 15.83 vs. AMS: 3.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.18  Med: 12.61 Max: 142.63
Current: 3.14
2.18
142.63
Revenue Growth (3Y)(%) -14.00
AMS's Revenue Growth (3Y)(%) is ranked lower than
89% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. AMS: -14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -44.3  Med: 1.70 Max: 27.8
Current: -14
-44.3
27.8
EBITDA Growth (3Y)(%) -12.10
AMS's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 123 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. AMS: -12.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AMS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -34.3  Med: 0.50 Max: 124.1
Current: -12.1
-34.3
124.1
» AMS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AMS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.65
AMS's P/B is ranked higher than
94% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 2.73 vs. AMS: 0.65 )
Ranked among companies with meaningful P/B only.
AMS' s 10-Year P/B Range
Min: 0.26  Med: 0.68 Max: 1.99
Current: 0.65
0.26
1.99
P/S 0.88
AMS's P/S is ranked higher than
71% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. AMS: 0.88 )
Ranked among companies with meaningful P/S only.
AMS' s 10-Year P/S Range
Min: 0.24  Med: 0.80 Max: 2.02
Current: 0.88
0.24
2.02
PFCF 8.06
AMS's PFCF is ranked higher than
88% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 21.92 vs. AMS: 8.06 )
Ranked among companies with meaningful PFCF only.
AMS' s 10-Year PFCF Range
Min: 0.86  Med: 2.49 Max: 56
Current: 8.06
0.86
56
POCF 2.05
AMS's POCF is ranked higher than
98% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 15.63 vs. AMS: 2.05 )
Ranked among companies with meaningful POCF only.
AMS' s 10-Year POCF Range
Min: 0.59  Med: 1.92 Max: 4.56
Current: 2.05
0.59
4.56
EV-to-EBIT 24.38
AMS's EV-to-EBIT is ranked lower than
60% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 20.07 vs. AMS: 24.38 )
Ranked among companies with meaningful EV-to-EBIT only.
AMS' s 10-Year EV-to-EBIT Range
Min: -1026.5  Med: 26.75 Max: 89
Current: 24.38
-1026.5
89
Current Ratio 0.77
AMS's Current Ratio is ranked lower than
76% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 1.29 vs. AMS: 0.77 )
Ranked among companies with meaningful Current Ratio only.
AMS' s 10-Year Current Ratio Range
Min: 0.36  Med: 1.50 Max: 4.13
Current: 0.77
0.36
4.13
Quick Ratio 0.77
AMS's Quick Ratio is ranked lower than
72% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. AMS: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
AMS' s 10-Year Quick Ratio Range
Min: 0.36  Med: 1.50 Max: 4.13
Current: 0.77
0.36
4.13
Days Sales Outstanding 91.24
AMS's Days Sales Outstanding is ranked lower than
89% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 46.60 vs. AMS: 91.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMS' s 10-Year Days Sales Outstanding Range
Min: 13.48  Med: 75.60 Max: 93.87
Current: 91.24
13.48
93.87

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.64
AMS's Price/Tangible Book is ranked higher than
95% of the 147 Companies
in the Global Medical Care industry.

( Industry Median: 3.78 vs. AMS: 0.64 )
Ranked among companies with meaningful Price/Tangible Book only.
AMS' s 10-Year Price/Tangible Book Range
Min: 0.27  Med: 0.77 Max: 1.83
Current: 0.64
0.27
1.83
Price/Projected FCF 0.27
AMS's Price/Projected FCF is ranked higher than
99% of the 90 Companies
in the Global Medical Care industry.

( Industry Median: 1.62 vs. AMS: 0.27 )
Ranked among companies with meaningful Price/Projected FCF only.
AMS' s 10-Year Price/Projected FCF Range
Min: 0.15  Med: 0.40 Max: 1.02
Current: 0.27
0.15
1.02
Price/Median PS Value 1.09
AMS's Price/Median PS Value is ranked higher than
55% of the 189 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. AMS: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
AMS' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 1.05 Max: 4.67
Current: 1.09
0.14
4.67
Earnings Yield (Greenblatt) (%) 4.16
AMS's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. AMS: 4.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 3.30 Max: 8.9
Current: 4.16
1.1
8.9
Forward Rate of Return (Yacktman) (%) 19.62
AMS's Forward Rate of Return (Yacktman) (%) is ranked higher than
73% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 11.00 vs. AMS: 19.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMS' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.6  Med: 19.20 Max: 56.7
Current: 19.62
1.6
56.7

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:AZS.Germany,
American Shared Hospital Services was incorporated in the State of California in 1983 and its predecessor, Ernest A. Bates, M.D., Ltd. (d/b/a American Shared Hospital Services), a California limited partnership, was formed in June 1980. It provides Gamma Knife stereotactic radiosurgery equipment and radiation therapy and related equipment to seventeen (17) medical centers in sixteen (16) states in the United States and two medical centers in Turkey, as of March 1, 2013. The Gamma Knife stereotactic radiosurgery is a non-invasive procedure and an alternative to conventional brain surgery or can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. Compared to conventional surgery, Gamma Knife radiosurgery usually involves shorter patient hospitalization, lower risk of complications and can be provided at a lower cost. Typically, Gamma Knife patients resume their pre-surgical activities one or two days after treatment. The Gamma Knife treats patients with 201 single doses of gamma rays that are focused with great precision on small and medium sized, well circumscribed and critically located structures in the brain. During 2006 Elekta introduced a new Gamma Knife model, the Perfexion unit, which treats patients with 192 single doses of gamma rays and will also provide the ability to perform procedures on areas of the upper cervical spine. The Gamma Knife delivers a concentrated dose of gamma rays from Cobalt-60 sources housed in the Gamma Knife. The Cobalt-60 sources converge at the target area and deliver a dose that is high enough to destroy the diseased tissue without damaging surrounding healthy tissue. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). Research is being conducted to determine whether the Gamma Knife can be effective in the treatment of epilepsy and other functional disorders. Conventional neurosurgery, radiation therapy and other radiosurgery devices are the primary competitors of Gamma Knife radiosurgery. The Medicare program is administered by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK